Merck & Co., Inc. $MRK Stock Purchased by Fulcrum Asset Management LLP

Key Points

• Fulcrum Asset Management increased its Merck stake by 148% in the third quarter, adding 17,924 shares to hold 30,036 shares valued at about $4.48 million.
• Merck reported quarterly earnings of $2.49 per share and revenue of $18.09 billion, beating analyst estimates; revenue rose 4.7% year over year.
• Merck has potential pipeline catalysts, including positive Phase 2b results for an investigational MASH treatment, but analysts flag 2027 headwinds from generic competition and slowing Keytruda growth. The stock carries a “Moderate Buy” consensus rating and an average price target of $155.74.

Fulcrum Asset Management LLP increased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 148.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 30,036 shares of the company's stock after acquiring an additional 17,924 shares during the period. Fulcrum Asset Management LLP's holdings in Merck & Co., Inc. were worth $4,484,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP grew its holdings in Merck & Co., Inc. by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock worth $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Bank of America Corp DE boosted its position in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Merck & Co., Inc. by 263.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company's stock valued at $347,334,000 after purchasing an additional 1,959,778 shares in the last quarter. Wellington Management Group LLP grew its stake in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Merck & Co., Inc. during the third quarter worth approximately $260,560,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president owned 36,613 shares of the company's stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 102,014 shares of company stock worth $13,608,779 over the last ninety days. 0.17% of the stock is owned by corporate insiders.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported positive Phase 2b results for efinopegdutide, an investigational weekly treatment for adults with MASH and stage F2 or F3 liver fibrosis. The findings add a potential new opportunity in liver disease, although the supplied report does not include detailed efficacy results. Article: Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide
• Positive Sentiment: Merck has started the Phase 3 ENHANCE-3 trial of OHTUVAYRE for COPD maintenance treatment. Separately, the FDA granted priority review to sacituzumab tirumotecan for endometrial cancer, advancing two potential growth drivers. Article: Merck Starts ENHANCE 3 COPD Trial As Cancer Drug Review Nears
• Neutral Sentiment: Merck’s collaboration with Tempus AI is expected to contribute to a five-year partnership value of roughly $192.5 million, providing a data and AI-related research tie-up; the article does not detail the financial impact to Merck. Article: The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Negative Sentiment: Analysts describe Merck’s 2027 growth outlook as challenging, citing generic competition, weaker vaccine performance and slowing growth for Keytruda. These pressures could weigh on near-term results, despite the company’s expanding pipeline. Article: MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

Analyst Ratings Changes

A number of brokerages recently issued reports on MRK. Scotiabank increased their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a "sector outperform" rating in a report on Tuesday, September 29th. The Goldman Sachs Group boosted their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a research note on Friday, August 21st. DZ Bank downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and set a $153.00 price objective on the stock. in a report on Tuesday, November 3rd. Freedom Broker raised their price objective on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a "hold" rating in a research note on Monday, November 2nd. Finally, Wolfe Research lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a report on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and an average price target of $155.74.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $148.49 on Tuesday. The company has a market capitalization of $366.34 billion, a PE ratio of 153.08, a PEG ratio of 6.83 and a beta of 0.13. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock's 50 day moving average price is $146.39 and its 200-day moving average price is $127.82. Merck & Co., Inc. has a twelve month low of $85.80 and a twelve month high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. The firm had revenue of $18.09 billion for the quarter, compared to analysts' expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The company's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 earnings per share. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.84 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine.

Founded in the United States in 1891, Merck & Co became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.